文献速递运动医学创伤骨科

妥布霉素与万古霉素在前交叉韧带同种异体移植物去污染体外模型中的比较

Tobramycin and Vancomycin in an In Vitro Model of Anterior Cruciate Ligament Allograft Decontamination.
PubMed 文献 · Am J Sports Med · 2024-02-02

本研究为控制性实验室研究,将表皮葡萄球菌ATCC 12228接种于人尸体股薄肌腱,用不同浓度的妥布霉素或万古霉素纱布包裹,比较细菌浓度降低效果。结果显示万古霉素(P=0.0001)和妥布霉素(P<0.0001)均能降低细菌浓度,妥布霉素在低至0.1 mg/mL时即达统计学显著降低,而万古霉素需低至2.5 mg/mL。作者结论为妥布霉素与万古霉素同样有效且可在更低剂量下实现。

要点

  • 妥布霉素在0.1 mg/mL浓度下即可显著降低表皮葡萄球菌浓度。
  • 万古霉素在2.5 mg/mL浓度下显著降低细菌浓度。
  • 作者认为妥布霉素可作为万古霉素的临床替代选择。

核心结论

  • 妥布霉素与万古霉素在降低细菌浓度方面同样有效,但妥布霉素可在更低剂量下达到该降低水平。
  • 作者指出需进一步研究阐明妥布霉素对肌腱组织的生物力学和细胞毒性作用,以巩固其作为前交叉韧带重建中万古霉素临床替代方案的地位。

研究设计与样本

  • 控制性实验室研究,将表皮葡萄球菌菌株ATCC 12228接种于人尸体股薄肌腱。
  • 肌腱用浸有不同实验浓度妥布霉素或万古霉素的无菌纱布包裹,回收残留细菌并系列稀释后平板菌落计数。
  • 采用双因素方差分析进行统计分析,P<.05认为有统计学意义。

主要发现

  • 万古霉素(P=0.0001)和妥布霉素(P<0.0001)均能降低细菌浓度。
  • 妥布霉素在低至0.1 mg/mL浓度时即产生统计学显著的细菌浓度降低(10分钟和20分钟时分别为P<0.0001和P=0.01)。
  • 万古霉素在低至2.5 mg/mL浓度时产生统计学显著的细菌浓度降低(10分钟和20分钟时均为P<0.0001)。

临床怎么用

  • 作者认为妥布霉素可作为前交叉韧带移植物去污染中万古霉素的替代选择。
  • 作者指出由于万古霉素相对频繁短缺,确立妥布霉素作为替代药物对骨科医生是有用的选择。

局限性

  • 原文结论指出需进一步研究阐明妥布霉素对肌腱组织的生物力学和细胞毒性作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 100,000 anterior cruciate ligament (ACL) reconstructions (ACLRs) occur annually in the United States, and postoperative surgical-site infection is a relatively rare but devastating complication, often leading to graft failure or septic arthritis of the knee, necessitating repeat surgery. Wrapping allografts in vancomycin-soaked gauze has been adopted as a common sterilization technique in the operating room to reduce surgical-site infection; however, identifying effective alternatives to vancomycin has not been extensively pursued. HYPOTHESIS: Tobramycin would be as effective as vancomycin in reducing the concentrations of Staphylococcus epidermidis bacteria on tendon allografts. STUDY DESIGN: Controlled laboratory study. METHODS: S. epidermidis strain ATCC 12228 was inoculated onto the human cadaveric gracilis tendon. The tendons were wrapped in sterile gauze saturated with tobramycin or vancomycin at various experimental concentrations. Bacteria remaining on the tendon were dislodged, serially diluted, and plated for colony counting. Statistical analysis was performed utilizing 2-way analysis of variance testing. Results were considered statistically significant when P < .05. RESULTS: Vancomycin (P = .0001) and tobramycin (P < .0001) reduced bacterial concentration. Tobramycin was found to produce a statistically significant reduction in bacterial concentration at concentrations as low as 0.1 mg/mL (P < .0001 and P = .01 at 10 and 20 minutes), while vancomycin produced a statistically significant reduction at a concentration as low as 2.5 mg/mL (P < .0001 at both 10 and 20 minutes). CONCLUSION: This study demonstrates that tobramycin is as effective as vancomycin in bacterial concentration reduction but can achieve this reduction level at lower doses. Further studies clarifying the biomechanical and cytotoxic effects of tobramycin on tendon tissue are indicated to solidify its use as a clinical alternative to vancomycin in ACLR. CLINICAL RELEVANCE: These results will begin establishing tobramycin as an alternative to vancomycin in ACL graft decontamination. Because of relatively frequent shortages of vancomycin, establishing tobramycin as an alternative agent is a useful option for the orthopaedic surgeon.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Bentkowski BN, Blunt KM, Milliron EM, et al. Tobramycin and Vancomycin in an In Vitro Model of Anterior Cruciate Ligament Allograft Decontamination. Am J Sports Med. 2024. PMID: 38305039. doi:10.1177/03635465231223138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。